170 related articles for article (PubMed ID: 9164218)
1. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
3. Unknown primary tumors metastatic to liver.
Ayoub JP; Hess KR; Abbruzzese MC; Lenzi R; Raber MN; Abbruzzese JL
J Clin Oncol; 1998 Jun; 16(6):2105-12. PubMed ID: 9626210
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
Pentheroudakis G; Briasoulis E; Karavassilis V; Fountzilas G; Xeros N; Samelis G; Samantas E; Pavlidis N
Acta Oncol; 2005; 44(2):155-60. PubMed ID: 15788295
[TBL] [Abstract][Full Text] [Related]
5. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
[TBL] [Abstract][Full Text] [Related]
6. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.
Abbruzzese JL; Abbruzzese MC; Hess KR; Raber MN; Lenzi R; Frost P
J Clin Oncol; 1994 Jun; 12(6):1272-80. PubMed ID: 8201389
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
8. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
9. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.
Hess KR; Abbruzzese MC; Lenzi R; Raber MN; Abbruzzese JL
Clin Cancer Res; 1999 Nov; 5(11):3403-10. PubMed ID: 10589751
[TBL] [Abstract][Full Text] [Related]
10. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Greco FA; Johnson DH; Hainsworth JD
Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
[TBL] [Abstract][Full Text] [Related]
11. [Metastatic carcinoma of unknown origin].
Fizazi K; Culine S
Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
[TBL] [Abstract][Full Text] [Related]
12. Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada.
Kim CS; Hannouf MB; Sarma S; Rodrigues GB; Rogan PK; Mahmud SM; Winquist E; Brackstone M; Zaric GS
Acta Oncol; 2015 Nov; 54(10):1781-7. PubMed ID: 25825957
[TBL] [Abstract][Full Text] [Related]
13. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
[TBL] [Abstract][Full Text] [Related]
14. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.
van de Wouw AJ; Janssen-Heijnen ML; Coebergh JW; Hillen HF
Eur J Cancer; 2002 Feb; 38(3):409-13. PubMed ID: 11818207
[TBL] [Abstract][Full Text] [Related]
17. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
[TBL] [Abstract][Full Text] [Related]
18. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.
Yamagishi H; Imai Y; Okamura T; Fukuda K; Ono Y; Ban S; Inoue T; Ueda Y
J Gastroenterol Hepatol; 2013 Dec; 28(12):1815-22. PubMed ID: 23808938
[TBL] [Abstract][Full Text] [Related]
19. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with cancer of unknown primary site.
Hainsworth JD; Greco FA
Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
